Among the many theories of fiduciary breach available to plaintiffs under the Employee Retirement Income Security Act of 1974 (“ERISA“), none has produced actual monetary liability for trustees and transaction insiders with the consistency of ESOP valuation litigation. Excessive-fee class actions against large defined contribution plans generate headlines, but they overwhelmingly resolve through insured settlements or defense verdicts grounded in procedural prudence. By contrast, ESOP valuation litigation, claims that a trustee caused an employee stock ownership plan to pay more than fair market value for employer securities, routinely ends in adjudicated findings of breach, joint and several liability, and eight-figure awards. The June 2025 arbitration award in Robertson v. Argent Trust Company, arising from the Isagenix Worldwide, Inc. ESOP, is the most instructive recent example, both for what it says about the substantive standard of care and for what it reveals about the procedural architecture (mandatory arbitration, party-in-interest liability, and fee-shifting) that now surrounds these disputes (Bailey Glasser 2025; Bradley Arant Boult Cummings 2026).
The Statutory Foundation
The doctrinal machinery is familiar. ERISA § 404(a) imposes duties of loyalty and prudence on plan fiduciaries, requiring that they act solely in the interest of participants and with the care, skill, and diligence of a prudent expert (29 U.S.C. § 1104). Section 406(a) prohibits transactions between a plan and a party in interest, including any sale or exchange of property, unless an exemption applies, and § 408(e) supplies the critical exemption for employer-stock acquisitions. The plan must pay no more than “adequate consideration,” meaning fair market value determined in good faith (29 U.S.C. §§ 1106, 1108). Section 409(a) then it supplies the teeth, “a breaching fiduciary is personally liable to make good all losses to the plan and to disgorge profits obtained through use of plan assets” (29 U.S.C. § 1109). Since Fifth Third Bancorp v. Dudenhoeffer, ESOP fiduciaries enjoy no presumption of prudence; they are held to the same standard as any other ERISA fiduciary, save the duty to diversify (573 U.S. 409 (2014)). The Supreme Court’s decision in Cunningham v. Cornell University further lowered the pleading bar for prohibited-transaction claims by treating § 408 exemptions as affirmative defenses rather than elements the plaintiff must negate (604 U.S. 693 (2025)). The result is a claims environment in which nearly every leveraged ESOP formation is presumptively litigable, and in which the trustee bears the practical burden of proving adequate consideration.
Robertson v. Argent Trust: Procedural History
Shana Robertson, a former Isagenix employee and ESOP participant, filed a putative class action in 2021 in the United States District Court for the District of Arizona, alleging that Argent Trust Company, as transactional trustee, breached its fiduciary duties and engaged in prohibited transactions by causing the ESOP to purchase Isagenix stock for more than fair market value in the 2018 formation transaction (Holland & Knight 2022). The first significant ruling was procedural: the court granted Argent’s motion to compel individual arbitration, enforcing the plan document’s arbitration clause and class action waiver (Robertson v. Argent Trust Co., No. 21-cv-01711-PHX-DWL, 2022 WL 2967710 (D. Ariz. July 27, 2022)). At the time, the decision was widely read as a defense victory, since individual arbitration was assumed to cap exposure at the value of a single participant account.
The subsequent history dismantled that assumption. In June 2024, the court permitted the plaintiff to add the selling shareholders’ trusts as defendants, and in June 2025, after seven days of evidentiary hearings, a unanimous arbitration panel found that Argent and the selling shareholders had engaged in prohibited transactions under ERISA and that Argent caused the ESOP to overpay by $38.25 million, . . . $1,275 per share (Bailey Glasser 2025; Bradley Arant Boult Cummings 2026). Although Robertson’s individual account damages were modest, approximately $11,029, the panel’s July 2025 fee award of roughly $2.36 million in attorneys’ fees plus $132,000 in costs demonstrated that individual arbitration is no economic shield when ERISA’s fee-shifting provision applies (Bailey Glasser 2025). A motion to confirm the awards was filed in the District of Arizona in October 2025, and the broader Isagenix ESOP claims proceeded toward resolution as the plan itself was liquidated for nominal value (Feinberg Jackson 2026).
Three Doctrinal Lessons: Robertson consolidates three propositions that define modern ESOP valuation litigation.
The arbitration “victory” is frequently pyrrhic. Compelling individual arbitration removes class exposure but substitutes a bench of arbitrators applying ERISA’s substantive standards, with fee-shifting intact and a $38.25 million overpayment finding on the record—a finding that other participants, and the Department of Labor, may deploy in parallel proceedings. The strategic calculus that favored arbitration clauses in ESOP plan documents after 2022 requires re-examination in light of the Robertson award (Bradley Arant Boult Cummings 2026).
Liability does not stop at the trustee. The panel held the selling shareholder trusts liable as parties in interest—an extension consistent with the Fourth Circuit’s holding in Walsh v. Vinoskey that a seller who knowingly participates in a prohibited transaction is jointly liable with the trustee for the ESOP’s overpayment, subject to equitable credits (985 F.4th, 4th Cir. 2021; Morgan Lewis 2022). The earlier district court decision in that litigation, Pizzella v. Vinoskey, had imposed $6.5 million in joint and several liability on the trustee and the selling shareholder after a bench trial dissecting the valuation methodology in granular detail, i.e., control premiums, working-capital assumptions, capitalization-of-earnings inputs, and the trustee’s failure to negotiate (400 F. Supp. 3d 437 (W.D. Va. 2019); Holland & Knight 2019). ESOP valuation litigation thus reaches sellers, their trusts, insiders who install the trustee, and increasingly—as a March 2026 Western District of North Carolina decision permitting claims against private equity investors and transaction counsel illustrates—the entire deal team (National Law Review 2026).
Process is the whole case. The Department of Labor’s $22.5 million consent judgment against Reliance Trust Company in the RVR, Inc. ESOP matter rested on allegations of a rushed, pre-ordained purchase of $105 million in company stock (U.S. Department of Labor 2023). The through-line from Vinoskey to RVR to Robertson is that adjudicators do not second-guess good-faith valuation judgments; they punish cursory due diligence, unexamined appraisals, absent negotiation, and divided loyalties. Where a trustee’s file demonstrates genuine interrogation of the financial advisor’s assumptions and arm’s-length price negotiation, courts have granted summary judgment even against novel theories (National Law Review 2026).
Implications for Fiduciaries
For the practitioner structuring an ESOP transaction, ESOP valuation litigation is no longer a tail risk; it is a base-case assumption. Personal liability under § 409(a) attaches to individual trustees and internal fiduciaries, not merely institutional ones, and indemnification from the plan sponsor is both legally fragile (courts have voided indemnification arrangements that ultimately burden the ESOP itself) and financially contingent on the sponsor’s solvency (Kantor & Kantor 2025). The prudent response is threefold: a documented, adversarial valuation process; genuine price negotiation memorialized in the record; and adequate fiduciary liability insurance, purchased before the transaction closes, with limits calibrated to the deal size rather than to statutory fidelity bond minimums. ERISA fidelity bonds protect the plan against dishonesty; they do nothing for the fiduciary facing a breach claim. Only fiduciary liability coverage responds to the defense costs and judgments that ESOP valuation litigation now reliably produces.
The trajectory from Dudenhoeffer through Cunningham to the Robertson award points in one direction: more claims, earlier survival past dismissal, and broader defendant pools. Trustees, selling shareholders, boards, and internal committee members who touch an ESOP transaction should assume their conduct will be reconstructed, years later, by an adversary with subpoena power and a fee-shifting statute. In that environment, the fiduciary’s best defenses are a meticulous record and a properly structured insurance program.
If you serve as an ESOP trustee, plan committee member, or director of an ESOP-owned company, the time to address your personal exposure is before the transaction, NOT after the demand letter arrives. An ERISA fidelity bond is NOT GOING TO SAVE YOU! The very limited coverage of an ERISA bond addresses only those perils associated with trustee dishonesty. Visit FiduciaryLiabilityCoverage.com for a confidential review of your fiduciary liability insurance program from underwriters who understand ESOP valuation litigation from the inside. Surety One, Inc. brings three decades of tradecraft and experience to the table. Follow our blog for up-to-date with our offers and changes in ERISA practice.
~ C. Constantin Poindexter, MA, JD, CPCU, AFSB, ASLI, ARe, AINS, AIS, CPLP
Bibliography
- Bailey Glasser LLP. 2025. “BG Moves to Confirm Arbitration Victory Finding Isagenix ESOP Overpaid $38 Million.” Bailey & Glasser, LLP. https://www.baileyglasser.com/news-BG-Moves-to-Confirm-Arbitration-Victory-in-Isagenix-ESOP.
- Bradley Arant Boult Cummings LLP. 2026. “Selling Shareholder Trusts Subject to ESOP Arbitration Award.” NCEO Employee Ownership Legal Digest / JD Supra. https://www.jdsupra.com/legalnews/selling-shareholder-trusts-subject-to-2041261/.
- Cunningham v. Cornell University, 604 U.S. 693 (2025).
- Employee Retirement Income Security Act of 1974, 29 U.S.C. §§ 1104, 1106, 1108, 1109.
- Feinberg Jackson Worthman & Wasow LLP. 2026. “Isagenix ESOP.” https://feinbergjackson.com/post_news/isagenix-esop-settlement/.
- Fifth Third Bancorp v. Dudenhoeffer, 573 U.S. 409 (2014).
- Holland & Knight LLP. 2019. “Court Awards ESOP $6.5 Million for Overpayment, Finds That Trustee Breached Duty.” https://www.hklaw.com/en/insights/publications/2019/08/court-awards-esop-65-million-for-overpayment.
- Holland & Knight LLP. 2022. “Court Compels Proposed ESOP Class to Individual Arbitration Based on Plan Document.” https://www.hklaw.com/en/insights/publications/2022/09/court-compels-proposed-esop-class-to-individual-arbitration.
- Kantor & Kantor LLP. 2025. “Current Trends in ESOP Indemnification Legal Disputes.” https://www.kantorlaw.net/the-continued-litigation-of-esop-indemnification-agreements/.
- Morgan Lewis & Bockius LLP. 2022. “Seller Beware! Selling Shareholders May Be Held Liable if ESOP Overpays Them for Shares.” ML BeneBits. https://www.morganlewis.com/blogs/mlbenebits/2022/03/seller-beware-selling-shareholders-may-be-held-liable-if-esop-overpays-them-for-shares.
- National Law Review. 2026. “North Carolina Federal Court Lets ESOP Fiduciary Claims Proceed, Underscoring Active Oversight Duties.” https://natlawreview.com/article/north-carolina-federal-court-lets-esop-fiduciary-claims-proceed-underscoring-active.
- National Law Review. 2026. “Federal Court Grants Summary Judgment in ESOP Releveraging Case, Rejecting Novel Dilution Theory.” https://natlawreview.com/article/federal-court-grants-summary-judgment-esop-releveraging-case-rejecting-novel.
- Pizzella v. Vinoskey, 400 F. Supp. 3d 437 (W.D. Va. 2019), aff’d in part, vacated in part sub nom. Walsh v. Vinoskey, 19 F.4th 672 (4th Cir. 2021).
- Robertson v. Argent Trust Co., No. 21-cv-01711-PHX-DWL, 2022 WL 2967710 (D. Ariz. July 27, 2022).
- U.S. Department of Labor. 2023. “Department of Labor Recovers $22.5M from Trustee for Stock Overpayment by RV Rental Company’s Employee Stock Ownership Plan.” News Release, September 13. https://www.dol.gov/newsroom/releases/ebsa/ebsa20230913.
